Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey Ostrove | M | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | - |
Alon Lazarus | M | 49 |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | - |
Julius Knowles | M | 61 |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | - |
Anna Phil | M | 36 |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | - |
Kathryn Swiderski | F | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | - |
Sourav Kole | M | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | 2 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kees Been
- Personal Network